Roivant Sciences Clinical Trial Data
Roivant and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). The drug met its primary and all key secondary endpoints in two identical trials, demonstrating a median time to treatment failure of over 48 weeks compared to 12 weeks for placebo, and the company plans to file a supplemental New Drug Application (sNDA) in the first half of 2027.